Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Noxopharm.
RELATED STOCKHEAD STORIES
Health & Biotech
Health Check: Control Bionics eyes 20pc revenue growth and ‘near term’ profitability
Health & Biotech
Alive and Kicking: Noxopharm has difficult brain cancer in its sights
News
Top 10 at 11: Copper finds and cancer drugs are in the morning news
News
Market Highlights: Oil, iron ore stocks on watch; and should we worry about the ‘September Effect’?
Health & Biotech
ASX Health Stocks: CBL targets more reimbursement revenue for NeuroNode device
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
ASX Health Stocks: Noxopharm soars 40pc on pancreatic tumour-tackling drug results
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Buyers ambush benchmark setting new benchmark
News
ASX Small Caps Lunch Wrap: Who’s thrown a giant sexy spanner in the works this week?
News
Market Highlights: Microsoft’s new AI chip, why divvy stocks aren’t a sure thing, and 5 small caps to watch
Health & Biotech
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Even the Aussie dollar appreciates a good lead as dynamic surge makes local IT the it sector for a day
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
ASX Biotech October Winners: Dimerix, Noxopharm and Chimeric dominate as investors hunt next big thing in pharma
Health & Biotech
